Cargando…

Decreased Serum Brain-Derived Neurotrophic Factor (BDNF) Levels in Patients with Alzheimer’s Disease (AD): A Systematic Review and Meta-Analysis

Findings from previous studies reporting the levels of serum brain-derived neurotrophic factor (BDNF) in patients with Alzheimer’s disease (AD) and individuals with mild cognitive impairment (MCI) have been conflicting. Hence, we performed a meta-analysis to examine the aggregate levels of serum BDN...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Ted Kheng Siang, Ho, Cyrus Su Hui, Tam, Wilson Wai San, Kua, Ee Heok, Ho, Roger Chun-Man
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358753/
https://www.ncbi.nlm.nih.gov/pubmed/30634650
http://dx.doi.org/10.3390/ijms20020257
_version_ 1783392056535678976
author Ng, Ted Kheng Siang
Ho, Cyrus Su Hui
Tam, Wilson Wai San
Kua, Ee Heok
Ho, Roger Chun-Man
author_facet Ng, Ted Kheng Siang
Ho, Cyrus Su Hui
Tam, Wilson Wai San
Kua, Ee Heok
Ho, Roger Chun-Man
author_sort Ng, Ted Kheng Siang
collection PubMed
description Findings from previous studies reporting the levels of serum brain-derived neurotrophic factor (BDNF) in patients with Alzheimer’s disease (AD) and individuals with mild cognitive impairment (MCI) have been conflicting. Hence, we performed a meta-analysis to examine the aggregate levels of serum BDNF in patients with AD and individuals with MCI, in comparison with healthy controls. Fifteen studies were included for the comparison between AD and healthy control (HC) (n = 2067). Serum BDNF levels were significantly lower in patients with AD (SMD: −0.282; 95% confidence interval [CI]: −0.535 to −0.028; significant heterogeneity: I(2) = 83.962). Meta-regression identified age (p < 0.001) and MMSE scores (p < 0.001) to be the significant moderators that could explain the heterogeneity in findings in these studies. Additionally, there were no significant differences in serum BDNF levels between patients with AD and MCI (eight studies, n = 906) and between MCI and HC (nine studies, n = 5090). In all, patients with AD, but not MCI, have significantly lower serum BDNF levels compared to healthy controls. This meta-analysis confirmed the direction of change in serum BDNF levels in dementia. This finding suggests that a significant change in peripheral BDNF levels can only be detected at the late stage of the dementia spectrum. Molecular mechanisms, implications on interventional trials, and future directions for studies examining BDNF in dementia were discussed.
format Online
Article
Text
id pubmed-6358753
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63587532019-02-06 Decreased Serum Brain-Derived Neurotrophic Factor (BDNF) Levels in Patients with Alzheimer’s Disease (AD): A Systematic Review and Meta-Analysis Ng, Ted Kheng Siang Ho, Cyrus Su Hui Tam, Wilson Wai San Kua, Ee Heok Ho, Roger Chun-Man Int J Mol Sci Review Findings from previous studies reporting the levels of serum brain-derived neurotrophic factor (BDNF) in patients with Alzheimer’s disease (AD) and individuals with mild cognitive impairment (MCI) have been conflicting. Hence, we performed a meta-analysis to examine the aggregate levels of serum BDNF in patients with AD and individuals with MCI, in comparison with healthy controls. Fifteen studies were included for the comparison between AD and healthy control (HC) (n = 2067). Serum BDNF levels were significantly lower in patients with AD (SMD: −0.282; 95% confidence interval [CI]: −0.535 to −0.028; significant heterogeneity: I(2) = 83.962). Meta-regression identified age (p < 0.001) and MMSE scores (p < 0.001) to be the significant moderators that could explain the heterogeneity in findings in these studies. Additionally, there were no significant differences in serum BDNF levels between patients with AD and MCI (eight studies, n = 906) and between MCI and HC (nine studies, n = 5090). In all, patients with AD, but not MCI, have significantly lower serum BDNF levels compared to healthy controls. This meta-analysis confirmed the direction of change in serum BDNF levels in dementia. This finding suggests that a significant change in peripheral BDNF levels can only be detected at the late stage of the dementia spectrum. Molecular mechanisms, implications on interventional trials, and future directions for studies examining BDNF in dementia were discussed. MDPI 2019-01-10 /pmc/articles/PMC6358753/ /pubmed/30634650 http://dx.doi.org/10.3390/ijms20020257 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ng, Ted Kheng Siang
Ho, Cyrus Su Hui
Tam, Wilson Wai San
Kua, Ee Heok
Ho, Roger Chun-Man
Decreased Serum Brain-Derived Neurotrophic Factor (BDNF) Levels in Patients with Alzheimer’s Disease (AD): A Systematic Review and Meta-Analysis
title Decreased Serum Brain-Derived Neurotrophic Factor (BDNF) Levels in Patients with Alzheimer’s Disease (AD): A Systematic Review and Meta-Analysis
title_full Decreased Serum Brain-Derived Neurotrophic Factor (BDNF) Levels in Patients with Alzheimer’s Disease (AD): A Systematic Review and Meta-Analysis
title_fullStr Decreased Serum Brain-Derived Neurotrophic Factor (BDNF) Levels in Patients with Alzheimer’s Disease (AD): A Systematic Review and Meta-Analysis
title_full_unstemmed Decreased Serum Brain-Derived Neurotrophic Factor (BDNF) Levels in Patients with Alzheimer’s Disease (AD): A Systematic Review and Meta-Analysis
title_short Decreased Serum Brain-Derived Neurotrophic Factor (BDNF) Levels in Patients with Alzheimer’s Disease (AD): A Systematic Review and Meta-Analysis
title_sort decreased serum brain-derived neurotrophic factor (bdnf) levels in patients with alzheimer’s disease (ad): a systematic review and meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358753/
https://www.ncbi.nlm.nih.gov/pubmed/30634650
http://dx.doi.org/10.3390/ijms20020257
work_keys_str_mv AT ngtedkhengsiang decreasedserumbrainderivedneurotrophicfactorbdnflevelsinpatientswithalzheimersdiseaseadasystematicreviewandmetaanalysis
AT hocyrussuhui decreasedserumbrainderivedneurotrophicfactorbdnflevelsinpatientswithalzheimersdiseaseadasystematicreviewandmetaanalysis
AT tamwilsonwaisan decreasedserumbrainderivedneurotrophicfactorbdnflevelsinpatientswithalzheimersdiseaseadasystematicreviewandmetaanalysis
AT kuaeeheok decreasedserumbrainderivedneurotrophicfactorbdnflevelsinpatientswithalzheimersdiseaseadasystematicreviewandmetaanalysis
AT horogerchunman decreasedserumbrainderivedneurotrophicfactorbdnflevelsinpatientswithalzheimersdiseaseadasystematicreviewandmetaanalysis